The study offers promising news for people with type 2 diabetes. By using SGLT2 inhibitors, they may be able to lower their ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6%.

Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...

A recent study suggests that type 2 diabetes can be reversed through a combination of calorie reduction, physical activity, ...

New research shows diabetes medication SGLT-2 inhibitors lower dementia risk by up to 35%, offering hope for millions ...

SGLT2 inhibitors significantly improves kidney health in a diverse group of Asian adults with Type 2 diabetes, study finds.

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

Learn how diabetes medications could revolutionize stroke prevention and enhance heart and brain health with breakthrough ...

People can reverse their type 2 diabetes through a combination of calorie cutting and medication, a small clinical trial says ...